title: Novel plant-derived target drugs: a step forward from licorice?
abstract: Isoliquiritigenin (ISL) is a chalcone compound with valuable pharmacological properties such as antioxidant, anti-inflammatory, anticancer and anti-allergic activities. With regard to anticancer property, ISL was able to suppress HIF-1α level, VEGF expression and secretion, cell migration and to decrease the expression and secretion of MMP-9/-2. These effects may be mediated through inhibition of p38, PI3K/Akt and NF-κB signaling pathways. Thus, low concentration of ISL may have therapeutic potential in the treatment of aggressive breast carcinoma and other neoplasms.
authors: Vito
authors: V
authors: Lorusso
authors: Ilaria
authors: I
authors: Marech
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D047188:Chalcones / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery; D005260:Female; D006035:Glycyrrhiza / Q000737:chemistry; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D047188:Chalcones; C040920:isoliquiritigenin